Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome - PubMed (original) (raw)
Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome
Steven A Schneider et al. Mod Pathol. 2014 May.
Free article
Abstract
Micropapillary urothelial carcinoma exhibits amplification of the human epidermal growth factor receptor, ERBB2(HER2), and overexpression of the ERBB2 protein product. The clinical significance of this has yet to be established. The objective of this study was to examine ERBB2 amplification and protein expression in micropapillary urothelial carcinoma and stage-matched typical urothelial carcinoma treated by radical cystectomy to assess the frequency of amplification and protein expression, and to determine the association with cancer-specific survival. Pathologic material and data from patients undergoing cystectomy at Mayo Clinic between 1980 and 2008 were reviewed. ERBB2 amplification by fluorescence in situ hybridization (FISH) and protein expression by immunohistochemistry were assessed. Univariate and multivariate Cox proportional hazards regression models were used to evaluate for associations of ERBB2 amplification and protein expression with survival. ERBB2 amplification was identified in 9 (15%) of 61 micropapillary carcinomas compared with 9 (9%) of 100 urothelial carcinomas. In patients with micropapillary carcinoma, ERBB2 amplification was associated with a nearly threefold increased risk of cancer death. ERBB2 amplification (hazard ratio 4.3; P=0.0008) remained associated with an increased risk of death from bladder cancer among patients with micropapillary urothelial carcinoma on multivariate analysis. The association of cancer-specific survival and ERBB2 amplification was not seen in patients with urothelial carcinoma. ERBB2 immunohistochemistry correlated with ERBB2 amplification but there was no association of ERBB2 protein expression and survival. ERBB2 amplification is more frequent in micropapillary urothelial carcinoma than typical urothelial carcinoma, and patients with micropapillary carcinoma who have ERBB2 amplification have worse cancer-specific survival than those who do not. Identification of ERBB2 amplification in micropapillary carcinoma could provide important prognostic information and possibly provide a role for ERBB2 targeted therapy.
Similar articles
- Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma.
Isharwal S, Huang H, Nanjangud G, Audenet F, Chen YB, Gopalan A, Fine SW, Tickoo SK, Lee BH, Iyer G, Chadalavada K, Rosenberg JE, Bajorin DF, Herr HW, Donat SM, Dalbagni G, Bochner BH, Solit DB, Reuter VE, Al-Ahmadie HA. Isharwal S, et al. Hum Pathol. 2018 Jul;77:63-69. doi: 10.1016/j.humpath.2018.03.015. Epub 2018 Mar 27. Hum Pathol. 2018. PMID: 29601842 Free PMC article. - Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma.
Behzatoğlu K, Yörükoğlu K, Demir H, Bal N. Behzatoğlu K, et al. Eur Urol Focus. 2018 Apr;4(3):399-404. doi: 10.1016/j.euf.2016.06.007. Epub 2016 Jun 21. Eur Urol Focus. 2018. PMID: 28753766 - HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization.
Ching CB, Amin MB, Tubbs RR, Elson P, Platt E, Dreicer R, Fergany A, Hansel DE. Ching CB, et al. Mod Pathol. 2011 Aug;24(8):1111-9. doi: 10.1038/modpathol.2011.69. Epub 2011 Apr 22. Mod Pathol. 2011. PMID: 21516078 - Clinicopathological Review of Micropapillary Urothelial Carcinoma.
Kumar D, Adeniran AJ. Kumar D, et al. Curr Oncol Rep. 2022 May;24(5):603-610. doi: 10.1007/s11912-022-01219-x. Epub 2022 Feb 24. Curr Oncol Rep. 2022. PMID: 35199295 Review. - Micropapillary urothelial carcinoma: clinico-pathologic review.
Perepletchikov AM, Parwani AV. Perepletchikov AM, et al. Pathol Res Pract. 2009;205(12):807-10. doi: 10.1016/j.prp.2009.07.016. Epub 2009 Sep 19. Pathol Res Pract. 2009. PMID: 19767154 Review.
Cited by
- Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer.
Leary JB, Enright T, Bakaloudi DR, Basnet A, Bratslavsky G, Jacob J, Spiess PE, Li R, Necchi A, Kamat AM, Pavlick DC, Danziger N, Huang RSP, Lin DI, Cheng L, Ross J, Talukder R, Grivas P. Leary JB, et al. Target Oncol. 2024 May;19(3):447-458. doi: 10.1007/s11523-024-01056-x. Epub 2024 Apr 3. Target Oncol. 2024. PMID: 38570422 - Molecular profile of bladder cancer progression to clinically aggressive subtypes.
Guo CC, Lee S, Lee JG, Chen H, Zaleski M, Choi W, McConkey DJ, Wei P, Czerniak B. Guo CC, et al. Nat Rev Urol. 2024 Jul;21(7):391-405. doi: 10.1038/s41585-023-00847-7. Epub 2024 Feb 6. Nat Rev Urol. 2024. PMID: 38321289 Review. - Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18.
Kim M, Lee JL, Shin SJ, Bae WK, Lee HJ, Byun JH, Choi YJ, Youk J, Ock CY, Kim S, Song H, Park KH, Keam B. Kim M, et al. ESMO Open. 2023 Aug;8(4):101588. doi: 10.1016/j.esmoop.2023.101588. Epub 2023 Jun 27. ESMO Open. 2023. PMID: 37385153 Free PMC article. Clinical Trial. - Precision Medicine in Bladder Cancer: Present Challenges and Future Directions.
Mohanty SK, Lobo A, Mishra SK, Cheng L. Mohanty SK, et al. J Pers Med. 2023 Apr 28;13(5):756. doi: 10.3390/jpm13050756. J Pers Med. 2023. PMID: 37240925 Free PMC article. Review. - HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role.
Sanguedolce F, Zanelli M, Palicelli A, Bisagni A, Zizzo M, Ascani S, Pedicillo MC, Cormio A, Falagario UG, Carrieri G, Cormio L. Sanguedolce F, et al. Int J Mol Sci. 2023 Feb 13;24(4):3720. doi: 10.3390/ijms24043720. Int J Mol Sci. 2023. PMID: 36835131 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous